Active — Not RecruitingNot Applicable

Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer

United States341 participantsStarted 2013-09-05

Plain-language summary

This study looks at the level of circulating tumor elements (cancer cells or DNA pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). Researchers will also compare the level and genetic characteristics of circulating tumor elements between individuals with rectal cancer and healthy individuals to understand how they may change over time. Information from this study may help researchers better understand rectal cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HEALTHY SUBJECT: No known diagnosis of colorectal cancer (CRC) or any other type of cancer for the last 10 years.(basal cell skin cancer is allowed). Subjects will be asked about their cancer history and a verbal confirmation is required * Any patient with diagnosis of rectal (or rectosigmoid) adenocarcinoma, including: * Patients with primary disease with or without neoadjuvant therapy; OR * Patients with recurrent disease with or without neoadjuvant therapy; OR * Patients with metastatic disease with or without prior treatment * No known current diagnosis of other invasive cancer; if prior diagnosis of other cancer, he/she has been free from cancer for \>= 3 years and is on no active treatment * Adequate mental and language capacity to provide consent

What they're measuring

Proportion of treatment naive locally advanced rectal cancer (LARC) patients with circulating tumor cells (CTC)

Timeframe: Baseline up to 6 years

Change in circulating tumor cells status

Timeframe: Baseline and 8 weeks after completion of treatment

Trial details

NCT IDNCT02874885

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-04-30